Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone Approved to Start US Trials of PD-L1 Candidate

publication date: Oct 16, 2018

CStone Pharmaceuticals of Suzhou announced US approval of its IND for CS1001, a novel PD-L1 candidate. CStone said the trial approval was the company's first in the US. Developed using Ligand's OMT transgenic animal platform, CS1001 is a fully human, full-length anti-PD-L1 monoclonal antibody, designed to mirror a natural G-type immune globulin 4 (IgG4) human antibody. Because of its design, CStone believes CS1001 will reduce the risk of immunogenicity and potential toxicities. The company started China trials of CS1001 one year ago. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital